Skip to content

Maria Beckman

5 papers in the library · 1 citation · publishing 2023-2026

Papers

Sort Most recent Most cited

Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled Trial

Research Square October 5, 2026 Anette Kjellgren, Johan Lundberg, Hampus Yngwe et al. preprint

Abstract Psilocybin treatment has emerged as a promising intervention for Major Depressive Disorder (MDD). However, the contribution of psychotherapeutic support to treatment outcomes remains unclear. This study explored therapists' descriptions of their work during a randomized, double-blind, placebo-controlled psilocybin treatment phase II trial for MDD. Nine therapists participated in...

DOI: 10.21203/rs.3.rs-10879308/v1 (opens in new tab) Full text (opens in new tab)

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder

Neuropsychopharmacology July 7, 2026 Wojciech Pasławski, Daniel Doyon, Carl Johan Ekman et al.

Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.

DOI: 10.1038/s41386-026-02490-3 (opens in new tab) Full text (opens in new tab) Major depressive disorder Psilocybin Downregulation and upregulation Mechanism of action +10

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression

JAMA Network Open May 15, 2026 Hampus Yngwe, Pontus Plavén-sigray, Carl Johan Ekman et al. 1 citation

Importance: Psilocybin has been proposed as a rapid-acting antidepressant (onset 6 weeks), but evidence from randomized clinical trials remains limited, particularly in the broader major depressive disorder (MDD) population. Objective: To assess short-term and long-term antidepressant effects of psilocybin therapy in patients with MDD. Design, Setting, and Participants: This double-blind,...

DOI: 10.1001/jamanetworkopen.2026.12589 (opens in new tab)

Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression.

BMC Medical Education April 9, 2026 Nikita Sanati Morel, Dea Siggaard Stenbæk, Johan Lundberg et al.

Major depression is a prevalent condition among patients with life-threatening illnesses, such as cancer, and recent findings suggest that psilocybin may hold promising treatment potential. Contemporary trials of psilocybin generally employ a model that includes psychotherapeutic support consisting of preparation and integration sessions surrounding the dosing. However, there is limited...

DOI: 10.1186/s12909-026-09124-8 (opens in new tab) Full text (opens in new tab) Psilocybin Cancer-related depression Facilitator training Nurses +4